News stories about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.526237009744 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of Aldeyra Therapeutics (NASDAQ ALDX) opened at 6.35 on Thursday. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $8.19. The company’s market cap is $39.66 million. The company’s 50-day moving average is $4.40 and its 200 day moving average is $4.66.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.02. Equities analysts anticipate that Aldeyra Therapeutics will post ($1.63) EPS for the current year.

Several research firms recently commented on ALDX. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Thursday, August 10th. Stifel Nicolaus reissued a “buy” rating and set a $16.00 price objective on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. Canaccord Genuity set a $12.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 14th. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, ValuEngine raised shares of Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $17.15.

WARNING: “Aldeyra Therapeutics (ALDX) Earns Daily Media Sentiment Score of 0.15” was reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/14/aldeyra-therapeutics-aldx-earns-daily-media-sentiment-score-of-0-15.html.

In other Aldeyra Therapeutics news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of the business’s stock in a transaction on Friday, June 30th. The shares were acquired at an average price of $4.60 per share, with a total value of $1,361,632.20. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 28.40% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Insider Buying and Selling by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.